Chronic gout: epidemiology, disease progression, treatment and disease burden.
BACKGROUND
Gout is a painful and disabling inflammatory arthritis of increasing prevalence associated with hyperuricemia and the deposition of monosodium urate crystals in soft tissues and joints. Diagnosed gout cases have been estimated at 2.13% of the 2009 US population. The highest incidence occurs in the 65+ year age group, with males more than twice as likely to be afflicted as females.


OBJECTIVE
To present the epidemiology of chronic gout and to discuss its disease burden.


METHODS
This commentary is based on expert opinion and supplemented with published/presented information identified through PubMed and rheumatology associations.


RESULTS
The steady rise of diagnosed gout cases can generally be linked to an aging population with multiple comorbidities, the use of certain prescription medications, and changes in diet and lifestyle. Progression to chronic gout has numerous causes such as poor compliance with, ineffectiveness of, or inability to tolerate prescribed regimens. Despite the availability of urate-lowering therapies (ULT), patients may either have contraindications to them or may not adequately respond. Patients with high flare frequency, tophi, and the inability to maintain serum urate levels below 6 mg/dL with ULT can be categorized as having chronic gout that is refractory, with a substantial disease burden. Based on lack of therapeutic options for urate-lowering for patients with chronic gout refractory to conventional therapy, the economic burden of this small but substantial population contributes disproportionately to the overall economic burden of chronic gout. Recent availability of gout-specific ICD-9-CM codes capturing the cost intense and impactful aspects of the disease - flares and tophi - is likely contribute to understanding the full health economic burden in gout.


CONCLUSIONS
The impact of chronic gout, especially if refractory to treatment, on functionality, productivity, quality of life and health care costs can be substantial and is deserving of future research.
The JeSTARx Group, Newfoundland, NJ, USA. RBrook@JeSTARx.com
Richard A
RA
Brook
Anna
A
Forsythe
James E
JE
Smeeding
N
N
Lawrence Edwards
D000368:Aged; D000369:Aged, 80 and over; D002908:Chronic Disease; D017281:Cost of Illness; D018450:Disease Progression; D004351:Drug Resistance / Q000502:physiology; D005260:Female; D006073:Gout / Q000191:economics / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy*; D006074:Gout Suppressants / Q000627:therapeutic use; D006801:Humans; D008297:Male; D015995:Prevalence
D006074:Gout Suppressants